7T MRS in Parkinson's Disease

University of Minnesota78 enrolled

Overview

This study is looking for healthy controls and patients with Parkinson's (PD) to perform an MR scan. 1. The neurochemical profile of the SN of patients with PD as measured by high field MRS will differ from that of healthy controls, in that glutathione will be lower due to oxidative stress, lactate will be higher due to mitochondrial dysfunction, the gliosis markers myo-inositol and glutamine will be higher due to inflammation (glial activation) and N-acetylaspartate and glutamate will be lower due to neuronal loss/damage. 2. There will be a relationship between neurochemical changes and disease severity.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Parkinson's Disease

Eligibility

Sex: ALLMin age: 45 YearsMax age: 75 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: Parkinson's disease Group * Parkinson's disease (clinical diagnostic criteria) * Age 45-75 years inclusive * Able to safely undergo MRI scanning * Absence of diabetes and smoking * Capable of giving informed consent Healthy Control Group * Age 45-75 years inclusive * Able to safely undergo MRI scanning * Absence of diabetes and smoking * Capable of giving informed consent Exclusion Criteria: Parkinson's disease Group * Dementia (clinically determined by PI Dr. Tuite) * Diagnosis of atypical parkinsonism * Inability to safely undergo MRI scanning * Inability to give informed consent * Unstable medical conditions * Present smoker * Diabetic (on oral or injectable medications for diabetes) * Taken coenzyme Q10 or Vitamin E in the 2 weeks prior to the scan * Does not meet age criteria Healthy Control Group * Has a 1st degree relative with PD * Dementia (clinically determined by PI Dr. Tuite) * Inability to safely undergo MRI scanning * Inability to give informed consent * Unstable medical conditions * Present smoker * Diabetic (on oral or injectable medications for diabetes) * Taken coenzyme Q10 or Vitamin E in the 2 weeks prior to the scan * Does not meet age criteria

Locations (1)

University of Minnesota/CMRR

Minneapolis, Minnesota, United States

Outcomes

Primary Outcomes

Magnetic resonance spectroscopy (MRS)

We will utilize optimized magnetic resonance spectroscopy (MRS) methodology to address theories of pathogenesis of Parkinson's disease (PD) by quantifying glutathione (GSH), lactate, glutamine and myo-inositol levels of the unilateral substantia nigra (SN) of healthy volunteers and patients with PD.

Time frame: Baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.